TY - JOUR
T1 - Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
AU - Liu, Huei Chun
AU - Chiu, Ming Jang
AU - Lin, Chin Hsien
AU - Yang, Shieh Yueh
N1 - Publisher Copyright:
© 2020 The Author(s) Published by S. Karger AG, Basel.
PY - 2020/3/26
Y1 - 2020/3/26
N2 - Blood biomarkers of Alzheimer's disease (AD) have attracted much attention of researchers in recent years. In clinical studies, repeated freeze/thaw cycles often occur and may influence the stability of biomarkers. This study aims to investigate the stability of amyloid-β 1-40 (Aβ1-40), amyloid-β 1-42 (Aβ1-42), and total tau protein (T-tau) in plasma over freeze/thaw cycles. Methods: Plasma samples from healthy controls (n = 2), AD patients (AD, n =3) and Parkinson's disease patients (PD, n = 3) were collected by standardized procedure and immediately frozen at -80°C. Samples underwent 5 freeze/thaw (-80°C/room temperature) cycles. The concentrations of Aβ1-40, Aβ1-42, and T-tau were monitored during the freeze/thaw tests using an immunomagnetic reduction (IMR) assay. The relative percentage of concentrations after every freeze/thaw cycle was calculated for each biomarker. Results: A tendency of decrease in the averaged relative percentages over samples through the freeze and thaw cycles for Aβ1-40 (100 to 97.11%), Aβ1-42 (100 to 94.99%), and T-tau (100 to 95.65%) was found. However, the decreases were less than 6%. For all three biomarkers, no statistical significance was found between the levels of fresh plasma and those of the plasma experiencing 5 freeze/thaw cycles (p > 0.1). Conclusions: Plasma Aβ1-40, Aβ1-42, and T-tau are stable through 5 freeze/thaw cycles measured with IMR.
AB - Blood biomarkers of Alzheimer's disease (AD) have attracted much attention of researchers in recent years. In clinical studies, repeated freeze/thaw cycles often occur and may influence the stability of biomarkers. This study aims to investigate the stability of amyloid-β 1-40 (Aβ1-40), amyloid-β 1-42 (Aβ1-42), and total tau protein (T-tau) in plasma over freeze/thaw cycles. Methods: Plasma samples from healthy controls (n = 2), AD patients (AD, n =3) and Parkinson's disease patients (PD, n = 3) were collected by standardized procedure and immediately frozen at -80°C. Samples underwent 5 freeze/thaw (-80°C/room temperature) cycles. The concentrations of Aβ1-40, Aβ1-42, and T-tau were monitored during the freeze/thaw tests using an immunomagnetic reduction (IMR) assay. The relative percentage of concentrations after every freeze/thaw cycle was calculated for each biomarker. Results: A tendency of decrease in the averaged relative percentages over samples through the freeze and thaw cycles for Aβ1-40 (100 to 97.11%), Aβ1-42 (100 to 94.99%), and T-tau (100 to 95.65%) was found. However, the decreases were less than 6%. For all three biomarkers, no statistical significance was found between the levels of fresh plasma and those of the plasma experiencing 5 freeze/thaw cycles (p > 0.1). Conclusions: Plasma Aβ1-40, Aβ1-42, and T-tau are stable through 5 freeze/thaw cycles measured with IMR.
UR - http://www.scopus.com/inward/record.url?scp=85083251316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083251316&partnerID=8YFLogxK
U2 - 10.1159/000506278
DO - 10.1159/000506278
M3 - Article
AN - SCOPUS:85083251316
SN - 1664-5464
VL - 10
SP - 46
EP - 55
JO - Dementia and Geriatric Cognitive Disorders Extra
JF - Dementia and Geriatric Cognitive Disorders Extra
IS - 1
ER -